semaglutide affect kidneys Ozempic and GLP-1 Drugs: Risk of Severe Side Effects significant 24% reduction in kidney

Wu J, Zhou R, Zhang Q et al (2024) Safety, pharmacokinetics, and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy subjects:a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial

HPLC testing verifies a purity level of 98%, ensuring reliable and reproducible research outcomes

Safety analyses included all participants who received at least one dose of the assigned intervention, with results summarized descriptively [1]

By creating drugs that can act as both GLP1R agonists and GIPR agonist , ( Dual agonist for short), the original aim was to create either additive or synergistic effects on insulin release for treating diabetes